Cervical cancer screening device company TruScreen has reported a 48% increase in sales for the year ending March 31 to $1.7 million compared to $1.1m the prior year, despite Covid disruption.
But the NZX and ASX-listed company incurred a net loss of $7.9m compared to $3.5m the year before after
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
